Protagonist Therapeutics PTGX Business Segments — Employee Expense Benefit Related To Discovery

Similar metrics at other companies

INSMReportable Segment — R&D compensation and benefit-related expenses

$72.14M+34.7%

LQD

LQDASingle Reportable — Labor And Related Expense

$31.65M+57.6%

EXELReportable Segment — Drug discovery

$19.48M+6.7%

RYTMSingle reportable segment — Labor and Related Expense

$58.65M+68.2%

RGTISingle Reportable — Labor And Related Expense

$10.57M+18.3%

RYTMSingle reportable segment — Preclinical, clinical and development expense

$18.51M-7.3%

Questions, answered.

What is Protagonist Therapeutics's business segments — employee expense benefit related to discovery?

Protagonist Therapeutics (PTGX) reported business segments — employee expense benefit related to discovery of $3.15M in Q1 2026.

How has Protagonist Therapeutics's business segments — employee expense benefit related to discovery changed year-over-year?

Protagonist Therapeutics's business segments — employee expense benefit related to discovery increased by 35.3% year-over-year, from $2.33M to $3.15M.

What is the long-term trend for Protagonist Therapeutics's business segments — employee expense benefit related to discovery?

Over 3 years (2022 to 2025), Protagonist Therapeutics's business segments — employee expense benefit related to discovery has grown at a 17.0% compound annual growth rate (CAGR), from $6.16M to $9.88M.

What does business segments — employee expense benefit related to discovery mean?

This represents the total cash-based compensation and benefits provided to personnel directly involved in the discovery phase of drug development. It reflects the investment in human capital required to maintain the company's proprietary technology platform. Changes in this metric indicate shifts in the size or cost of the research team dedicated to early-stage innovation.